期刊文献+

微小残留病在监测儿童急性T淋巴细胞白血病复发中的意义 被引量:4

Clinical significance of minimal residual disease in monitoring relapse of childhood acute T-cell lymphoblastic leukemia
在线阅读 下载PDF
导出
摘要 目的探讨微小残留病(MRD)监测急性T淋巴细胞白血病患儿复发的临床指导意义。方法采用四色流式细胞术对2006年8月1日-2008年4月1日32例急性T淋巴细胞白血病住院患儿在治疗不同时间点进行追踪监测,分析不同MRD水平与患儿的临床反应及复发之间的关系。结果诱导治疗第33天以及诱导治疗结束巩固治疗前(治疗12周)MRD<10-4和≥10-4两组患儿的复发率差异有显著性(P=0.003,P=0.002)。结论监测急性T淋巴细胞白血病患儿MRD水平,在评估早期治疗反应、监测复发以及估计预后中具有重要临床价值。 ObjectiveTo observe the clinical significance of monitoring minimal residual disease in childhood acute T-cell lymphoblastic leukemia.MethodsMinimal residual disease level of 32 children with T-cell ALL from 2006.8.1-2008.4.1 were monitored by 4-color flow cytometry in different therapy time point.The relationship between minimal residual disease level and early treatment response,as well as relapse were studied.ResultsThere were significant differences between the relapse and complete remission groups divided by MRD level(MRD≥10^-4 or MRD10^-4) in the early 33rd day of induction therapy and before consolidation therapy.The P values were 0.003 and 0.002 respectively.ConclusionSequential monitoring MRD by 4-color follow cytometry in different therapy time point could evaluate the early response and provides highly significant prognostic information in children with T-cell ALL.
出处 《中国小儿血液与肿瘤杂志》 CAS 2011年第5期203-206,共4页 Journal of China Pediatric Blood and Cancer
基金 北京市科委资助项目"儿童急性淋巴细胞白血病微小残留病定量及其对个体化治疗的作用"(项目编号:D0905001040431)
关键词 白血病 T淋巴细胞型 急性 儿童 微小残留病 childhood T-cell lymphoblastic leukemia minimal residual disease
  • 相关文献

参考文献12

  • 1Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol,2003, 21:3616-3622.
  • 2Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med, 2006,354: 166-178.
  • 3PuUen J, Shuster J J, Link M, et al. Singnificance of commonly used prognostic factors differs for children with T cell acute lymphoblastic leukemia (ALL) as compared to those with B-precursor ALL. A Pediatric Oncology Group(POG) study. Leukemia, 1999, 13: 1696-1707.
  • 4Barowitz MJ, Pullen DJ, Shuster JJ. Minimal residual disease detection in childhood precursor-B--cell acute lymphoblastic leukemia: relation to other risk factors. A Children' s Oncology Group study. Leukemia, 2003,17 : 1566-1576.
  • 5Kerst G, Kreyenberg H, Roth C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Hematol, 2005, 128:774-782.
  • 6Coustan-Smith E, Gajjar A, Hijlya N, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia, 2004,18:499-504.
  • 7Coustan-Smith E, Sancho J, Behm FG, et al. prognostic importance of measuring of early clearance of Leukemia cells by follow cytometry in childhood acute lymphoblastic leukemia. Blood, 2002, 100: 52-58.
  • 8Campana D, Coustain-Simth E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemla. Best Pract Res Clin Haematol, 2002,15:1-19.
  • 9Pui CH, Compana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia, 2000,14:783-785.
  • 10Bruggemann M, Schrauder A, Raft T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18 20 September 2008. Leukemia, 2010,24:521-535.

同被引文献52

  • 1Pui CH, Evans WE. Treatment of acute lyrnphoblastic leuke- mia[J]. N Engl J Med, 2006, 354: 166-178.
  • 2Pui CH, Robison LL, Look AT. Acute lymphoblastic leukae- mia[J]. Lancet, 2008, 371: 1030-1043.
  • 3Schrappe M. Risk-adapted stratification and treatment of child- hood acute lymphoblastic leukaemia [J]. Radiat Prot Dosime- try, 2008,132 (2):130-133.
  • 4Mfiricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unseleet- ed pediatric and adolescent patients enrolled in the trial ALL-BFM 95[J]. Blood, 2008,111 (9):4477-4489.
  • 5Yamaji K, Okamoto T, Yokota S, et al. Minimal residual dis- ease-based augmented therapy in childhood acute lymphoblas- tie leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group [J]. Pediatr Blood Cancer, 2010, 55(7) :1287-1295.
  • 6Stow P, Key L, Chen X, et al. Clinical significance of low lev- els of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia [J]. Blood, 2010,115(23):4657-4663.
  • 7Campana D. Minimal residual disease in acute lymphoblastic leukemia [J]. Hematol Am Soc Hematol Educ Program, 2010, 2010:7-12.
  • 8Szczepafiski T. Why and how to quantify minimal residual dis- ease in acute lymphoblastic leukemia? [ J ]. Leukemia, 2007,21 (4):622-626.
  • 9Denys B, van der Sluijs-Gelling A J, Homburg C, et al. Im- proved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia [J]. Leukemia, 2012 Aug 16 [Epub ahead of print] .
  • 10Scrideli CA, Assump:ao JG, Ganazza MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lympho- blastic leukemia into good and poor outcome groups [J]. Hae- matologica, 2009, 94(6):781-789.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部